

CIN: L15142RJ1991PLC006353

# SARDA PROTEINS LTD.

Date: 02.09.2020

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.


Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter ended on 30<sup>th</sup> June, 2020 along with Limited review report on the Un-audited Financial Results of the company for the quarter ended on 30<sup>th</sup> June, 2020.

You are requested to kindly take the same on record.

Thanking You,  
Yours Faithfully

FOR SARDA PROTEINS LTD  
For SARDA PROTEINS LTD.



Company Secretary

AMIT KUMAR MODI  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
M.NO.: 29371

Encl: a/a



*Khetawat Agarwal & Co.*  
Chartered Accountants

**Limited Review Report**  
**Unaudited Standalone Quarterly and Year to Date Results**

To  
The Board of Directors  
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter ended 30<sup>th</sup> June 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Khetawat Agarwal & Co.**

Chartered Accountants

FRN: 003960C



**M.L. Agarwal**


Partner

M. No.: 072854

UDIN : 20072854AAAAW9876

Place : Jaipur

Date : 02.09.2020



---

Office: 103, 1<sup>st</sup> Floor, City Centre, Ashok Circle, Alwar - 301001 (Rajasthan)

Phone : Office 0144-2340924, 7014347644

Mobile: 9414215353 (ML Agarwal)

E-mail : khetawatagarwal21@gmail.com

**SARDA PROTEINS LIMITED**

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)  
Corporate office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)  
Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com

CIN: L15142RJ1991PLC006353

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020**

Rs.in Lakhs

Particulars	Three Months Ended on	Preceding Three Months Ended on	Corresponding Three Month	Year Ended
	30.06.2020	31.03.2020	30.06.2019	31.03.2020
	Un-Audited	Audited	Un-Audited	Audited
I. Revenue from operations	-	188.61	37.75	540.03
II. Other Income	2.01	1.98	0.01	8.02
<b>III. Total Revenue (I+II)</b>	<b>2.01</b>	<b>190.59</b>	<b>37.76</b>	<b>548.05</b>
IV. Expenses:				
Cost of Material Consumed	-	-	-	-
Purchase of Stock -in- Trade	-	174.39	37.25	512.69
Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-
Employee Benefit Expenses	2.84	0.23	3.37	9.06
Finance Cost	-	0.18	0.01	0.21
Depreciation and Amortisation Expenses	0.08	0.08	0.20	0.33
Other expenses	3.19	2.28	4.22	8.72
<b>Total Expenses (IV)</b>	<b>6.11</b>	<b>177.16</b>	<b>45.05</b>	<b>531.01</b>
V. Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(4.11)	13.43	(7.29)	17.04
VI. Exceptional Items	-	-	-	-
VII. Profit/(Loss) before Extraordinary Items and Tax (V-VI)	(4.11)	13.43	(7.29)	17.04
VIII. Extraordinary Items	-	-	-	-
IX. Profit/(Loss) before Tax (V-VI)	(4.11)	13.43	(7.29)	17.04
X. Tax Expense:				
(1) Current Tax	-	2.66	-	2.66
(2) Deferred Tax	-	11.09	-	11.09
XI. Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(4.11)	(0.32)	(7.29)	3.29
XII. Profit/(Loss) from Discontinued Operations	-	-	-	-
XIII. Tax Expenses of Discontinued Operations	-	-	-	-
XIV. Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-
XV. Profit/(Loss) for the period (IX+XII)	(4.11)	(0.32)	(7.29)	3.29
XVI. Other Comprehensive Income				
A (i) Items will not be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-
B (i) Items will be reclassified to Profit or Loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
<b>Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)</b>	<b>(4.11)</b>	<b>(0.32)</b>	<b>(7.29)</b>	<b>3.29</b>
Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59
XVIII Earnings per Equity Share				
(1) Basic	(0.24)	(0.02)	(0.42)	0.19
(2) Diluted	(0.24)	(0.02)	(0.42)	0.19

**Notes:**

- The above results were approved by Audit Committee and Board of Directors in their meeting held on 02nd September 2020.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable, as company dealing in only one segment i.e. "Agro Products".
- No Investor Complaints were received during the quarter ended 30-Jun-2020 nor any pending as on 01-Jul-2020.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.
- Due to the COVID-19 situation business of the company was been impacted during the quarter, and not achieved any business deal during the quarter.

Place: Jaipur  
Date : 02nd September-2020



For and on behalf of the Board  
Sarda Proteins Ltd

Deepak Data (DIN: 01672415)  
Managing Director



UDIN:-20072854AAAAAW9876